Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
592.50B
Market cap592.50B
Price-Earnings ratio
22.28
Price-Earnings ratio22.28
Dividend yield
2.09%
Dividend yield2.09%
Average volume
9.59M
Average volume9.59M
High today
$245.90
High today$245.90
Low today
$244.43
Low today$244.43
Open price
$244.43
Open price$244.43
Volume
635.30K
Volume635.30K
52 Week high
$247.25
52 Week high$247.25
52 Week low
$141.50
52 Week low$141.50

Stock Snapshot

As of today, Johnson & Johnson(JNJ) shares are valued at $245.86. The company's market cap stands at 592.5B, with a P/E ratio of 22.28 and a dividend yield of 2.1%.

On 2026-02-25, Johnson & Johnson(JNJ) stock traded between a low of $244.43 and a high of $245.90. Shares are currently priced at $245.86, which is +0.6% above the low and -0.0% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 635.3K, against a daily average of 9.59M.

During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $247.25 at its peak.

During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $247.25 at its peak.

JNJ News

Simply Wall St 2h
Will Philadelphia Talc Verdict Reshape Johnson & Johnson's Legal Overhang and Earnings Resilience Narrative?

Recently, a Philadelphia jury found Johnson & Johnson liable in a talc ovarian cancer case, awarding US$250,000 in compensatory and punitive damages over allege...

Will Philadelphia Talc Verdict Reshape Johnson & Johnson's Legal Overhang and Earnings Resilience Narrative?
TipRanks 17h
Johnson & Johnson submits sBLA to FDA for approval of Imaavy

Johnson & Johnson announced the submission of a supplemental Biologics License Application to the U.S. FDA seeking approval of Imaavy as the first-ever treatmen...

Simply Wall St 1d
Johnson & Johnson Valuation Check After New Drug Approvals And US$1b Cell Therapy Investment

Johnson & Johnson (JNJ) has packed several clinically focused announcements into February, including new subcutaneous dosing approvals for RYBREVANT, long term...

Johnson & Johnson Valuation Check After New Drug Approvals And US$1b Cell Therapy Investment

Analyst ratings

57%

of 28 ratings
Buy
57.1%
Hold
35.7%
Sell
7.1%

More JNJ News

Nasdaq 1d
Bayer Sues J&J Over Prostate Cancer Treatment Promotion Dispute

(RTTNews) - German pharmaceutical and life sciences major Bayer AG (BAYRY.PK, BAYZF.PK) announced that it has filed false advertising suit against Johnson & Joh...

Bayer Sues J&J Over Prostate Cancer Treatment Promotion Dispute
Simply Wall St 2d
ORIC Cancer Pipeline Progress And Big Pharma Partnerships Reshape Risk Profile

ORIC Pharmaceuticals (NasdaqGS:ORIC) reports progress in its cancer therapy pipeline, with lead drug candidates entering Phase 1b clinical trials. The company...

ORIC Cancer Pipeline Progress And Big Pharma Partnerships Reshape Risk Profile
TipRanks 2d
“J&J’s Claims of Superiority… Are False”: Johnson & Johnson Stock Rises despite Bayer Lawsuit

German drugmaker Bayer (BAYRY) for the second time this year came at Johnson & Johnson (JNJ) with a new lawsuit. However, the American health giant’s shares def...

TipRanks 2d
Johnson & Johnson Stock Flat despite First Co-funding Agreement with Blackstone

Healthcare giant Johnson & Johnson’s (JNJ) shares failed to get off the ground in Monday’s pre-market trading. This is despite entering its first co-funding agr...

Nasdaq 2d
Blackstone Life Sciences Signs Deal With JNJ To Jointly Fund Clinical Development Of Bleximenib

(RTTNews) - Blackstone Life Sciences, a division of Blackstone Inc. (BX), Monday announced a research and development funding agreement with Johnson & Johnson (...

Blackstone Life Sciences Signs Deal With JNJ To Jointly Fund Clinical Development Of Bleximenib
Simply Wall St 3d
Johnson And Johnson Weighs DePuy Sale As Governance Approach Shifts

Johnson & Johnson (NYSE:JNJ) is preparing a potential sale of its DePuy Synthes orthopedics unit that could exceed $20b. The company has also dropped formal di...

Johnson And Johnson Weighs DePuy Sale As Governance Approach Shifts
Nasdaq 3d
Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio

Key Points Johnson & Johnson is a core player in global healthcare. A diverse portfolio, fortress-like balance sheet, and industry tailwinds cement a growing...

Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.